Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia.

Arnold FW, Summersgill JT, Ramirez JA.

Semin Respir Crit Care Med. 2016 Dec;37(6):819-828. Epub 2016 Dec 13. Review.

PMID:
27960206
2.

Mixed cryoglobulinemia and secondary membranoproliferative glomerulonephritis associated with ehrlichiosis.

Caster DJ, Summersgill JT, Paueksakon P, Massung RF, Shieh WJ, McLeish KR.

CEN Case Rep. 2014 Nov;3(2):178-182. doi: 10.1007/s13730-014-0113-6. Epub 2014 Mar 8.

3.

Point-of-care testing for community-acquired pneumonia.

Drancourt M, Gaydos CA, Summersgill JT, Raoult D.

Lancet Infect Dis. 2013 Aug;13(8):647-9. doi: 10.1016/S1473-3099(13)70165-8. No abstract available.

PMID:
23886323
4.

Phenotypic differences in virulence and immune response in closely related clinical isolates of influenza A 2009 H1N1 pandemic viruses in mice.

Camp JV, Chu YK, Chung DH, McAllister RC, Adcock RS, Gerlach RL, Wiemken TL, Peyrani P, Ramirez JA, Summersgill JT, Jonsson CB.

PLoS One. 2013;8(2):e56602. doi: 10.1371/journal.pone.0056602. Epub 2013 Feb 18.

5.

Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation.

Borel N, Pospischil A, Dowling RD, Dumrese C, Gaydos CA, Bunk S, Hermann C, Ramirez JA, Summersgill JT.

J Clin Pathol. 2012 Feb;65(2):171-7. doi: 10.1136/jclinpath-2011-200270. Epub 2011 Nov 2.

PMID:
22049224
6.

Immunoproteomic identification and serological responses to novel Chlamydia pneumoniae antigens that are associated with persistent C. pneumoniae infections.

Bunk S, Susnea I, Rupp J, Summersgill JT, Maass M, Stegmann W, Schrattenholz A, Wendel A, Przybylski M, Hermann C.

J Immunol. 2008 Apr 15;180(8):5490-8.

7.

Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas.

Borel N, Summersgill JT, Mukhopadhyay S, Miller RD, Ramirez JA, Pospischil A.

Atherosclerosis. 2008 Jul;199(1):154-61. Epub 2007 Oct 29.

PMID:
18028932
8.

A worldwide perspective of atypical pathogens in community-acquired pneumonia.

Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Rello J, Menendez R, Marzoratti L, Luna CM, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Am J Respir Crit Care Med. 2007 May 15;175(10):1086-93. Epub 2007 Mar 1.

PMID:
17332485
9.

Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection.

Borel N, Mukhopadhyay S, Kaiser C, Sullivan ED, Miller RD, Timms P, Summersgill JT, Ramirez JA, Pospischil A.

BMC Infect Dis. 2006 Oct 19;6:152.

10.

Identification of Chlamydia pneumoniae proteins in the transition from reticulate to elementary body formation.

Mukhopadhyay S, Good D, Miller RD, Graham JE, Mathews SA, Timms P, Summersgill JT.

Mol Cell Proteomics. 2006 Dec;5(12):2311-8. Epub 2006 Aug 18.

11.

Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response.

Mukhopadhyay S, Miller RD, Sullivan ED, Theodoropoulos C, Mathews SA, Timms P, Summersgill JT.

Infect Immun. 2006 Jul;74(7):3853-63.

12.

Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infections.

Polkinghorne A, Hogan RJ, Vaughan L, Summersgill JT, Timms P.

Microbes Infect. 2006 Jan;8(1):61-72. Epub 2005 Jul 22.

PMID:
16269262
13.

Analysis of altered protein expression patterns of Chlamydia pneumoniae by an integrated proteome-works system.

Mukhopadhyay S, Miller RD, Summersgill JT.

J Proteome Res. 2004 Jul-Aug;3(4):878-83.

PMID:
15359744
14.

Detailed protocol for purification of Chlamydia pneumoniae elementary bodies.

Mukhopadhyay S, Clark AP, Sullivan ED, Miller RD, Summersgill JT.

J Clin Microbiol. 2004 Jul;42(7):3288-90.

15.

Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.

Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, Ramirez JA, Summersgill JT.

Antimicrob Agents Chemother. 2004 Jul;48(7):2538-43.

16.

Chlamydial persistence: beyond the biphasic paradigm.

Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P.

Infect Immun. 2004 Apr;72(4):1843-55. Review. No abstract available.

18.

Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha.

Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, Ramirez JA, Summersgill JT.

J Infect Dis. 2002 Jun 1;185(11):1631-6. Epub 2002 May 17.

PMID:
12023769
19.

Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells.

Molestina RE, Klein JB, Miller RD, Pierce WH, Ramirez JA, Summersgill JT.

Infect Immun. 2002 Jun;70(6):2976-81.

20.
21.

Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.

Pantoja LG, Miller RD, Ramirez JA, Molestina RE, Summersgill JT.

Infect Immun. 2001 Dec;69(12):7927-32.

22.

Inhibition of oxidative burst and chemotaxis in human phagocytes by Legionella pneumophila zinc metalloprotease.

Sahney NN, Summersgill JT, Ramirez JA, Miller RD.

J Med Microbiol. 2001 Jun;50(6):517-25.

PMID:
11393289
23.
24.

Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells.

Molestina RE, Miller RD, Lentsch AB, Ramirez JA, Summersgill JT.

Infect Immun. 2000 Jul;68(7):4282-8.

25.

Collaborative multidisciplinary workshop report: interface of lipid metabolism, atherosclerosis, and Chlamydia infection.

Byrne GI, Skarlotos SI, Grunfeld C, Kalayoglu MV, Libby P, Saikku P, Summersgill JT, Wyrick P.

J Infect Dis. 2000 Jun;181 Suppl 3:S490-1. No abstract available.

PMID:
10839745
26.

Interactions of Chlamydia pneumoniae with human endothelial cells.

Summersgill JT, Molestina RE, Miller RD, Ramirez JA.

J Infect Dis. 2000 Jun;181 Suppl 3:S479-82. Review.

PMID:
10839743
27.
28.

Signal transduction during Legionella pneumophila entry into human monocytes.

Coxon PY, Summersgill JT, Ramirez JA, Miller RD.

Infect Immun. 1998 Jun;66(6):2905-13.

29.

Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism.

Mehta SJ, Miller RD, Ramirez JA, Summersgill JT.

J Infect Dis. 1998 May;177(5):1326-31.

PMID:
9593020
30.
31.

Use of heteroduplex analysis to classify legionellae on the basis of 5S rRNA gene sequences.

Pinar A, Ahkee S, Miller RD, Ramirez JA, Summersgill JT.

J Clin Microbiol. 1997 Jun;35(6):1609-11.

32.

Chlamydia pneumoniae infection in patients with cystic fibrosis.

Emre U, Bernius M, Roblin PM, Gaerlan PF, Summersgill JT, Steiner P, Schachter J, Hammerschlag MR.

Clin Infect Dis. 1996 May;22(5):819-23.

PMID:
8722938
33.

Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells.

Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC.

Infect Immun. 1996 May;64(5):1614-20.

34.
35.

Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha.

Summersgill JT, Sahney NN, Gaydos CA, Quinn TC, Ramirez JA.

Infect Immun. 1995 Jul;63(7):2801-3.

36.

Rapid tests for the diagnosis of Legionella infections.

Ramirez JA, Summersgill JT.

J Ky Med Assoc. 1994 Feb;92(2):62-5.

PMID:
8163902
37.

Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular Legionella pneumophila.

Ramirez JA, Summersgill JT, Miller RD, Meyers TL, Raff MJ.

J Antimicrob Chemother. 1993 Jul;32(1):93-9.

PMID:
8226420
38.

Killing of Legionella pneumophila by nitric oxide in gamma-interferon-activated macrophages.

Summersgill JT, Powell LA, Buster BL, Miller RD, Ramirez JA.

J Leukoc Biol. 1992 Dec;52(6):625-9.

PMID:
1464734
39.
40.
41.

Bactericidal activity of imipenem compared to erythromycin against intracellular Legionella pneumophila.

Ramirez JA, Summersgill JT, Miller RD, Meyers TL, Raff MJ.

Drugs Exp Clin Res. 1992;18(10):407-10.

PMID:
1306151
42.

Absence of bacteremia during nasal septoplasty.

Silk KL, Ali MB, Cohen BJ, Summersgill JT, Raff MJ.

Arch Otolaryngol Head Neck Surg. 1991 Jan;117(1):54-5.

PMID:
1986761
43.

Inhibition of polymorphonuclear leukocyte function by Legionella pneumophila exoproducts.

Sahney NN, Lambe BC, Summersgill JT, Miller RD.

Microb Pathog. 1990 Aug;9(2):117-25.

PMID:
2177516
44.

Merifluor-Legionella cross-reactivity.

Summersgill JT, Snyder JW.

J Clin Microbiol. 1990 Jul;28(7):1680. No abstract available.

45.

Interactions of virulent and avirulent Legionella pneumophila with human monocytes.

Summersgill JT, Raff MJ, Miller RD.

J Leukoc Biol. 1990 Jan;47(1):31-8.

PMID:
2152938
46.

Interactions of virulent and avirulent Legionella pneumophila with human polymorphonuclear leukocytes.

Summersgill JT, Raff MJ, Miller RD.

Microb Pathog. 1988 Jul;5(1):41-7.

PMID:
2854187
47.
48.

Azlocillin and cefonicid penetration into bone enhanced by probenecid.

Summersgill JT, Harrod LG, Raff MJ.

Antimicrob Agents Chemother. 1984 Sep;26(3):292-4.

49.
50.

Metronidazole treatment of Bacteroides fragilis infections.

Melo JC, Raff MJ, Wunderlich HF, Chun CH, Summersgill JT, Varghese R.

Am J Med Sci. 1980 Nov-Dec;280(3):143-9.

PMID:
7457495

Supplemental Content

Loading ...
Support Center